What diseases and indications does fenelinone mainly treat?

Finerenone is a novel nonsteroidal mineralocorticoid receptor (MR) antagonist specifically designed to reduce tissue inflammation and fibrosis caused by excessive activation of aldosterone. Its main indication is to treat patients with chronic kidney disease (CKD) accompanied by type 2 diabetes, aiming to delay the deterioration of renal function and reduce the incidence of cardiovascular events. This indication has been approved by the US FDA and the EU EMA, and is gradually being promoted globally.

In such patients, aldosterone induces local inflammatory response and fibrous deposition in the kidney by activating the MR pathway, leading to glomerulosclerosis and decreased renal function. Although traditional treatments such as ACEI or ARB can inhibit the RAAS system, they are still insufficient to alleviate aldosterone escape and fibrosis progression. Fennelidone provides a new cardiorenal protection mechanism by directly blocking MR.

In addition to delayingeGFR decline, Finerenone has also been proven to effectively reduce proteinuria levels, indirectly reflecting its protective effect on the glomerular filtration barrier. More importantly, it can also significantly reduce the risk of heart failure hospitalization and cardiovascular mortality, which makes it increasingly important in the management of CKD and cardiovascular comorbidities.

In the future, fenelidone may also be explored for other fibrosis-related diseases, such as primary hyperaldosteronism, heart failure with preserved ejection fraction (HFpEF), liver fibrosis and even some rare genetic kidney diseases. Multiple clinical trials are currently ongoing to further expand its potential indications.

In summary, fenelidone is not only a therapeutic drug for chronic kidney disease, but also plays an important role in the heart-kidney linkage mechanism. Its broad-spectrum anti-inflammatory and anti-fibrosis mechanism marks the shift of kidney disease treatment from traditional blood pressure control and proteinuria reduction to deeper mechanism intervention.

Reference materials:https://www.kerendia.com/